J I Mullins
Overview
Explore the profile of J I Mullins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
148
Citations
5747
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hertz T, Logan M, Rolland M, Magaret C, Rademeyer C, Fiore-Gartland A, et al.
Vaccine
. 2016 Oct;
34(47):5792-5801.
PMID: 27756485
Introduction: The Merck Adenovirus-5 Gag/Pol/Nef HIV-1 subtype-B vaccine evaluated in predominately subtype B epidemic regions (Step Study), while not preventing infection, exerted vaccine-induced immune pressure on HIV-1 breakthrough infections. Here...
2.
Celum C, Wald A, Lingappa J, Magaret A, Wang R, Mugo N, et al.
N Engl J Med
. 2010 Jan;
362(5):427-39.
PMID: 20089951
Background: Most persons who are infected with human immunodeficiency virus type 1 (HIV-1) are also infected with herpes simplex virus type 2 (HSV-2), which is frequently reactivated and is associated...
3.
Malhotra U, Nolin J, Horton H, Li F, Corey L, Mullins J, et al.
Vaccine
. 2009 Sep;
27(48):6678-87.
PMID: 19747576
To understand how broad recognition of HIV-1 variants may be achieved we examined T-cell reactivity in newly infected persons as well as vaccine recipients to a broad spectrum of potential...
4.
Mullins J, Jensen M
Curr Top Microbiol Immunol
. 2006 Mar;
299:171-92.
PMID: 16568899
Human immunodeficiency viruses (HIV) have exhibited an extraordinary capacity for genetic change, exploring new evolutionary space after each transmission to a new host. This presents a great challenge to the...
5.
Doria-Rose N, Learn G, Rodrigo A, Nickle D, Li F, Mahalanabis M, et al.
J Virol
. 2005 Aug;
79(17):11214-24.
PMID: 16103173
Human immunodeficiency virus type 1 (HIV-1) is a difficult target for vaccine development, in part because of its ever-expanding genetic diversity and attendant capacity to escape immunologic recognition. Vaccine efficacy...
6.
Gottlieb G, Mullins J
AIDS Res Hum Retroviruses
. 2001 Nov;
17(16):1563-5, 1567.
PMID: 11709101
No abstract available.
7.
Anderson J, Rodrigo A, Learn G, Wang Y, Weinstock H, Kalish M, et al.
J Mol Evol
. 2001 Oct;
53(1):55-62.
PMID: 11683323
Phylogenetic analyses frequently rely on models of sequence evolution that detail nucleotide substitution rates, nucleotide frequencies, and site-to-site rate heterogeneity. These models can influence hypothesis testing and can affect the...
8.
Shankarappa R, Chatterjee R, Learn G, Neogi D, Ding M, Roy P, et al.
J Virol
. 2001 Oct;
75(21):10479-87.
PMID: 11581417
India is experiencing a rapid spread of human immunodeficiency virus type 1 (HIV-1), primarily through heterosexual transmission of subtype C viruses. To delineate the molecular features of HIV-1 circulating in...
9.
Kreisberg J, Kwa D, Schramm B, Trautner V, Connor R, Schuitemaker H, et al.
J Virol
. 2001 Aug;
75(18):8842-7.
PMID: 11507229
It has been hypothesized that human immunodeficiency virus type 1 (HIV-1) evolves toward increased cytopathicity in conjunction with disease progression in infected patients. A viral property known to evolve in...
10.
Frey S, Hoover E, Mullins J
J Virol
. 2001 May;
75(11):5433-40.
PMID: 11333931
The process of feline immunodeficiency virus (FIV) cell entry was examined using assays for virus replication intermediates. FIV subtype B was found to utilize the chemokine receptor CXCR4, but not...